News
Video
Author(s):
Expert urologist Naveen Kella, MD, shares his perspective on the advent of PSMA PET-CT imaging in patients with prostate cancer, addressing both benefits and limitations to this approach.
Ultra-low PSA responses are more prevalent with darolutamide plus ADT
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025
Most men in EMBARK trial recover T levels following treatment suspension
Dr. Murphy on increasing diversity in cancer clinical trials
FDA clears AI-powered application for measuring prostate volume
Study shows IsoPSA’s predictive ability for clinically significant prostate cancer